Post by Deleted on Mar 10, 2016 15:06:44 GMT
IRVINE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- ChromaDex Corp. (CDXC), an innovator of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today the initiation of the second human clinical trial for its patented ingredient, NIAGEN® (Nicotinamide Riboside - NR).
The second human clinical trial will build upon the results of the Company’s first human clinical trial announced in February 2015 which demonstrated that a single oral dose of NIAGEN® is a safe, effective nicotinamide adenine dinucleotide (NAD+) precursor in humans. The results of that study constituted a significant milestone as it showed for the first time an increase in NAD+ in humans has been demonstrated through NR supplementation.
The second human clinical trial will be a randomized, double-blind, placebo controlled parallel study in 140 healthy adults ranging in age from 40-60, which will examine the benefits of NIAGEN® if taken daily for eight consecutive weeks. The outcome will provide key information on the effective dose range of NIAGEN® to increase the mitochondrial co-enzyme NAD+ and NAD+ metabolite concentrations in the body..
C L
